No black box warning on record for Glyxambi
As of the latest FDA labeling reviewed, Glyxambi (EMPAGLIFLOZIN AND LINAGLIPTIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Glyxambi medicine page for the complete safety profile.